A randomized, multicenter study comparing the efficacy of recombinant FSH vs recombinant FSH with Ganirelix during superovulation/IUI therapy

• Published in: American journal of obstetrics and gynecology Vol. 191; no. 2; pp. 648 - 651
• Main Authors: Stan Williams, R., Hillard, Jessica B., De Vane, Gary, Yeko, Tim, Kipersztok, Simon, Rhoton-Vlasak, Alice, Sistrom, Chris
• Format: Journal Article
• Language: English
• Published: United States Mosby, Inc 01.08.2004
• Subjects: Adult; Antagon; Drug Therapy, Combination; Female; Follicle Stimulating Hormone, Human - therapeutic use; Ganirelix; GnRH antagonists; Gonadotropin-Releasing Hormone - analogs & derivatives; Gonadotropin-Releasing Hormone - antagonists & inhibitors; Gonadotropin-Releasing Hormone - therapeutic use; Humans; Infertility; Infertility, Female - therapy; Insemination, Artificial - methods; Pregnancy; Pregnancy Outcome; Pregnancy Rate; Superovulation; Superovulation/intrauterine insemination; Treatment Outcome; Superovulation/intrauterine insemination; Pregnancy rate; GnRH antagonists; Antagon; Infertility; Ganirelix
• ISSN: 0002-9378; 1097-6868
• DOI: 10.1016/j.ajog.2004.06.072

The purpose of this study was to determine if use of a Gonadotropin releasing hormone (GnRH) antagonist, Ganirelix (Antagon), can improve pregnancy rates during superovulation with recombinant follicle-stimulating hormone (rFSH) followed by intrauterine insemination (IUI). This was a multicenter, prospective, randomized, open-label, assessor-blind, controlled trial of females (n=54), ages 18 to 39 undergoing superovulation/IUI with up to 4 cycles of superovulation/IUI without Ganirelix (n=66), or up to 4 cycles of superovulation/IUI with the addition of Ganirelix (n=52). No statistically significant difference in clinical pregnancy rates per cycle initiated was found for patients in the treatment or control group (12% vs 7%, P=.29). Other variables assessed, including endometrial thickness, size of follicles, peak serum estradiol levels, mid-lutea progesterone levels, and total vials of rFSH used also showed no statistically significant difference. Superovulation/IUI cycles using Ganirelix produce similar pregnancy rates when compared with cycles not using a GnRH antagonist, although there is a trend towards better pregnancy rates in cycles with Ganirelix.